Neptune Welcomes Dr. Graham Wood as Chief Scientific Officer

Published: April 11, 2019

Neptune Welcomes Dr. Graham Wood as Chief Scientific Officer

Neptune Wellness Solutions Inc. is pleased to announce that Dr. Graham Wood will be joining the Company’s management team as Chief Scientific Officer (CSO) as of May 1st, 2019. With the creation of this new position, Neptune takes a significant step further in executing on its strategy toward global leadership in the offering of value added, differentiated science-based products for the legal cannabis and nutrition consumer product markets.

Dr. Wood, holder of a Ph.D. in Neurology and Neurosurgery from McGill University, is a distinguished researcher and executive and a recognized leader in the clinical pharmacology of cannabis with experience with combustible, vaping, sublingual and oral oils and capsules formulations of cannabis. He has conducted over 400 clinical pharmacology studies with companies such as Phoenix International, MDS Pharma, Allied Research and Cetero and was CEO at Manna Research (a late phase clinical CRO). He was most recently Chief R&D Officer at Altasciences, where he led cannabis research.

“We are delighted to welcome someone of Graham’s stature to steer our scientific efforts. Both cannabis and nutrition are global consumer product industries that hinge on value-added, differentiated and science-based products and Graham’s proven expertise will be invaluable in supporting Neptune’s leading capabilities in this regard,” said Jim Hamilton, President and CEO of Neptune.

“Science is key to the development of effective condition-specific cannabinoid products for medical, wellness and lifestyle consumers. I am excited to join Neptune, whose long-standing experience in the health and wellness consumer product sector makes it ideally positioned to thrive in the global marketplace as the cannabis and the health and nutrition markets become increasingly intertwined”, said Wood.

As CSO, Wood will lead Neptune’s research and development strategy, product development efforts and clinical programs. Wood will also oversee Neptune’s global regulatory strategy, health product delivery technologies, and intellectual property portfolio.